Diddy On Trial Diddy's ex-assistant tells court she ‘hasn't lied to anyone at all'
Sean 'Diddy' Combs' former employee, who has given evidence under the pseudonym 'Mia', has been questioned by Diddy's defence lawyer.
In court on Thursday, 'Mia' told the court she had been raped and sexually assaulted by Diddy.
Today, defence lawyer Brian Steel suggested 'Mia' had made up sexual assault allegations. He questioned her about a scrapbook she had made for Sean 'Diddy' Combs birthday, as well as videos and multiple Instagram posts she had made, which all painted Diddy in a glowing light.
Anoushka Mutanda-Dougherty speaks to BBC New York correspondent Nada Tawfik about the day in court, as week three of the trial ends.
Sean 'Diddy' Combs is on trial in New York, facing federal charges of sex trafficking, racketeering with conspiracy and transportation for prostitution. He denies all the charges.
The Diddy on Trial podcast is here to investigate the rumours, confront the theories, and give you the answers that you need.
We also want YOU to be part of the conversation. Have you any questions about the case? Heard a theory that doesn't sit right with you? Get in touch now via WhatsApp: 0330 123 555 1.
Details of organisations in the UK offering information and support with some of the issues raised are available at bbc.co.uk/actionline
Presenter: Anoushka Mutanda-Dougherty
Series Producer: Laura Jones
Sound Design: Mark Burrows
Senior Digital Producer: Matthew Pintus
Executive Producer: Richard Fenton-Smith
Production Coordinator: Hattie Valentine
Editor: Clare Fordham
Commissioning Editor: Rhian Roberts
Assistant Commissioner: Will Drysdale
Commissioning Producer: Adam Eland
Commissioning Assistant Producer: Rechmial Miller
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
AP PHOTOS: Fishermen say a new natural gas project off Senegal's coast threatens their livelihoods
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging. At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story. The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it. Your support makes all the difference.
Telegraph
an hour ago
- Telegraph
Cancer patients live 40pc longer after experimental treatment
Cancer patients given experimental treatment that programmes the body to attack rogue cells live 40 per cent longer, major research shows. Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy where a patient's own T-cells – a type of white blood cell – are altered in a lab to target and kill cancer cells. The engineered cells are then reintroduced into the patient's bloodstream. CAR T-cell therapy works by genetically engineering a patient's T-cells to recognise and destroy cancer cells. T-cells are a type of white blood cell that can recognise and destroy foreign cells, including cancer cells, but because cancer is very good at evading immune detection, they often miss their mark. CAR T-cells are engineered to make them better at detecting cancer cells. The pioneering therapy had already been hailed by scientists as one of the most significant breakthroughs in treatment for its success in treating blood cancers. Now, new findings suggest it could also revolutionise treatment for solid tumours. Experts at the American Society of Clinical Oncology 's (Asco) annual meeting in Chicago, the world's largest cancer conference, said the findings heralded 'a new generation of treatment'. Solid tumours represent roughly 90 per cent of all adult human cancers, including breast, lung and pancreatic cancer. Currently, over 650 CAR-Ts are in active development for a solid tumour indication. The new study – the first ever randomised controlled trial of CAR T-cell therapy in solid tumours – involved patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer. 'A paradigm shift' Those given the radical treatment lived on average approximately 40 per cent longer than patients who received standard care, a clinical trial found. The results have been simultaneously published in the medical journal The Lancet. Dr Carl June, a leading expert on CAR T-cell therapy at the University of Pennsylvania, who was not involved with the trial, said the findings were 'groundbreaking'. He said: 'This is an exciting study showing the first positive results from a randomised trial testing CAR T-cells for a solid cancer.' In the trial, over 100 patients in China with advanced gastric or GEJ cancer were randomised to receive either CAR T-cell therapy or one of the standard-of-care medications. Patients who received CAR T-cell therapy lived an average of 7.9 months after randomisation, compared to 5.5 months with standard care. Patients receiving the designer immunotherapy also experienced 3.3 months without the cancer advancing, versus 1.8 months in the standard care group. The researchers, from Peking University Cancer Hospital and Institute in Beijing, said CAR-T-cell therapy 'showed a statistically significant improvement in progression-free survival and clinically meaningful improvement in overall survival'. The results suggest CAR T-cell 'could represent a paradigm shift' in care, addressing a crucial unmet need for some patients, they added. A second study on CAR T-cell led by the University of Pennsylvania and due to be presented at Asco on Sunday, suggested the approach could also be used to treat brain tumours. Results from that trial are expected to show CAR T-cell can shrink tumours in glioblastoma, a notoriously aggressive and fast-growing brain cancer, and help patients live much longer. Oncologists in Chicago said they were increasingly optimistic about the potential of the therapy to revolutionise treatment of solid tumours, after dramatic success with blood cancers. Dr John Haanen, of the Netherlands Cancer Institute, who will deliver a presentation on CAR T-cell therapy at the Asco meeting, said the breakthroughs suggest 'a new generation of treatment that wasn't there for medical oncologists before'. Dr Catherine Elliott, director of research at Cancer Research UK, said: 'CAR T-cell therapy – a highly personalised treatment that modifies a patient's own immune cells to recognise and destroy their cancer – has already shown success in treating some blood cancers, but it hasn't yet worked well for solid tumours.' She said it was 'encouraging' to see early signs that it might help those with advanced stomach or gastroesophageal junction cancer, who lived an extra two and a half months longer than those given standard care.
The Guardian
an hour ago
- The Guardian
The New York Knicks' season is over, but a divisive inquest has only just begun
Almost immediately after the Knicks' playoff run ended on Saturday night in Indianapolis, the fan discourse in New York began to closely resemble American politics: hyperbolic, binary and allergic to nuance. But the truth about this team – and Tom Thibodeau's coaching – lies somewhere in the messy middle. The Knicks are out. They were eliminated by the Indiana Pacers for the second straight, bowing out from the Eastern Conference finals in six games instead of last year's seven-game loss in the East semis. As the franchise's best season in a generation comes to a close, New York are trying to figure out how to feel. Knicks fandom is a hell of a place. Like the US political scene, it allows only two positions: praise or condemnation. Rational analysis rarely gains traction. Hyperbole prevails. It's two sides of the same rotten coin. This season wasn't a referendum on Thibodeau's genius or ineptitude. It was something more complicated: a year of real progress, missed chances and rising expectations. One faction scapegoats Thibodeau without fully understanding their critiques. Some want him fired and replaced by Queens native Michael Malone – who was just fired himself. Others float assistants like Chris Quinn, but can't articulate his philosophy beyond buzzwords. Often, these arguments mask a lack of understanding more than a coherent vision. Meanwhile, another camp defends Thibodeau's every move, refusing to question his substitution patterns, rigid rotations or reliance on hard zone. Terms like 'drop coverage' and 'schemes' have become lazy shorthand for tribalized opinions. But just like the disappearing middle ground in national discourse, the truth lies somewhere in between. This was the Knicks' first trip to the Eastern Conference finals in 25 years. That progress only happened because ownership finally stepped aside. Once James Dolan hired former agent Leon Rose and gave him room to operate, the team pivoted from star-chasing to smart-drafting, financially-disciplined and culture-building. Rose hired Thibodeau, his former client, to instill a ready-to-work mentality, then brought in Jalen Brunson, who emerged as a legitimate MVP candidate. Last summer Rose doubled down, cashing in draft capital and depth to reunite Brunson with Villanova teammate Mikal Bridges and adding Karl-Anthony Towns, OG Anunoby and Josh Hart. That core delivered 51 wins and propelled New York to fifth in offensive rating (117.3) and eighth in net rating (4.0). They gutted out a first-round win over Detroit, then stunned top-seeded Boston in six behind a lethal Brunson-Towns pick-and-roll and a defense that played the gaps and switched more aggressively than at any point in the regular season. But against Indiana, their momentum stalled. The Pacers' fast-paced 10-man rotation overwhelmed New York. They sent waves of defenders at Brunson, while Andrew Nembhard turned in the best defensive series of his career. After that epic collapse in the series opener, Thibodeau had already shortened the rotation to seven for Game 2. He brought in Mitchell Robinson and Deuce McBride to shore up the pick-and-roll defense, where Brunson and Towns are most vulnerable. In Game 3, Thibodeau improvised, going nine-deep. Towns scored 20 of his 24 points in the fourth quarter to erase a 20-point deficit. Delon Wright and Landry Shamet were crucial on the defensive end. But in Game 4, neither Wright nor Shamet played in the third quarter, when Indiana seized control. They returned in the fourth, but Thibodeau closed with his usual starters, a group that was minus-20 in the series and minus-41 across the playoffs. Despite being plus-8 in Game 3, McBride, Wright and Shamet never shared the floor together in Game 4. Thibodeau's most damaging choice may have been closing with Hart over McBride, who had barely guarded Tyrese Haliburton. Ironically, Thibodeau made the same decisions in Game 5, but the Knicks won and critics went quiet. Wright and Shamet again sat the third quarter. Robinson again didn't close. The hypocrisy of Thibs detractors borders on performative. The Knicks played from behind in nearly every playoff game except Game 5. Critics use this as justification to call for Thibodeau's dismissal. But 17 turnovers in Games 4 and 6 – not a product of coaching – were decisive. The team's 19.5 assists per game in the series weren't on Thibodeau either. He ran a wide array of actions – horn sets, pin-downs, DHO, high pick-and-roll – but Indiana smothered secondary options, forcing Brunson and Towns into iso-heavy, low-efficiency looks. Brunson recorded just five assists to Towns across the entire series. That lack of connection played right into Rick Carlisle's hands. His game plan –blitzing on switches, walling off Hart and Bridges in the lane – was clinical. Carlisle outcoached Thibodeau. But there's no shame in that. Carlisle is a champion and one of the sharpest minds in the game. Every player in the Knicks' main seven-man rotation had a fatal flaw: Bridges' handle, Anunoby's rebounding, Hart's shooting, Robinson's durability, McBride's playmaking. Thibodeau isn't a fraud or a genius. He gave fans what they asked for: deeper rotations, experimental lineups, extended minutes for the Towns-Robinson twin tower pairing. It still wasn't enough. The Pacers were simply better. Now it's on Rose to retool the roster. That likely starts with keeping Robinson as the starting center and reconsidering Hart's role. His lack of shooting limits five-out spacing and his defense, once a calling card, has regressed. He struggled consistenly on switches and blew key rotations. Brunson and Towns remain elite offensively, but both are liabilities in transition and in ball-screen coverage. The Knicks' regular-season defense was 2.8 points per 100 possessions better with Towns off the floor. In the playoffs, that gap narrowed –but problems remained. Thibodeau tried everything: starting Robinson, pre-switching with Anunoby, plugging in Hart. When Towns dropped, Indiana hit jumpers. When he switched, they beat him off the dribble. By Game 6, the starting unit had a minus-33 defensive rating. Poor communication plagued them all season. This wasn't a collapse. It was a ceiling. The Knicks are no longer a punchline. They're a real team with real stakes and real expectations. Every game in this series was winnable. They weren't embarrassed, but they were outplayed. Visibility brings volume, however. The higher the stakes, the louder the takes. Knicks fandom now operates like a two-party system. Its future may depend on whether fan – and the franchise – can embrace complexity instead of shouting past each other.
